Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2 Positive Metastatic Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02028364
What this trial is testing

Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women

Who this might be right for
Breast Cancer
Jules Bordet Institute 55
Testing effectiveness (Phase 2)Looking for participantsNCT05868226
What this trial is testing

PRE-ISPY Phase I/II Oncology Platform Program

Who this might be right for
HER2-positive Breast CancerMetastatic CancerMetastatic Breast Cancer+29 more
QuantumLeap Healthcare Collaborative 280
Not applicableNot Yet RecruitingNCT05980208
What this trial is testing

A Real-world Study of Inetetamab for First-line Treatment of MBC

Who this might be right for
Breast CancerReal-world Study
Hunan Cancer Hospital 150
Early research (Phase 1)Ended earlyNCT06878248
What this trial is testing

Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer MetastaticLocally Advanced Breast Cancer (LABC)Malignant Neoplasm of Breast+3 more
Calibr, a division of Scripps Research 10
Early research (Phase 1)Study completedNCT03251378
What this trial is testing

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers

Who this might be right for
Advanced Solid TumorsMetastatic Colon CancerMetastatic Breast Cancer+4 more
Hutchison Medipharma Limited 129
Large-scale testing (Phase 3)Study completedNCT03262935
What this trial is testing

SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Byondis B.V. 437
Early research (Phase 1)Active Not RecruitingNCT04692831
What this trial is testing

Testing a New Imaging Agent to Identify Cancer

Who this might be right for
HER-2 Positive Malignant Carcinoma of BreastHER-2 Protein OverexpressionHER2-positive Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center 60
Testing effectiveness (Phase 2)Ended earlyNCT01934894
What this trial is testing

Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases

Who this might be right for
Metastatic Breast Cancer With Intracranial Metastases
SCRI Development Innovations, LLC 11
Early research (Phase 1)Ended earlyNCT01238029
What this trial is testing

Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerHER2 PositiveFirst or Second Line Therapy+1 more
Sponsor GmbH 12
Large-scale testing (Phase 3)UnknownNCT03863223
What this trial is testing

Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 590
Testing effectiveness (Phase 2)Looking for participantsNCT04923542
What this trial is testing

SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases

Who this might be right for
Brain MetastasesHR+ Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 31
Not applicableStudy completedNCT06676436
What this trial is testing

Observational Study on the Treatment of Patients With Metastatic Breast Cancer

Who this might be right for
Cancer
AstraZeneca 204
Testing effectiveness (Phase 2)Study completedNCT00773344
What this trial is testing

Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin

Who this might be right for
Solid TumorsBreast Cancer
Bristol-Myers Squibb 25
Testing effectiveness (Phase 2)Looking for participantsNCT06450314
What this trial is testing

Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.

Who this might be right for
Metastatic Breast CancerHER2-positive Breast Cancer
UNICANCER 170
Not applicableEnded earlyNCT00358098
What this trial is testing

Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
AHS Cancer Control Alberta 51
Large-scale testing (Phase 3)UnknownNCT05861830
What this trial is testing

Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)

Who this might be right for
Advanced Breast Cancer
Peking Union Medical College Hospital 80
Not applicableStudy completedNCT04460898
What this trial is testing

RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.

Who this might be right for
Breast Cancer
Pfizer 195
Not applicableStudy completedNCT07108595
What this trial is testing

Efficacy and Safety of T-DXd in Patients With HER2-positive and HER2-low Metastatic Breast Cancer: a Real-world Study

Who this might be right for
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 142
Post-approval studies (Phase 4)UnknownNCT04767828
What this trial is testing

A Single Arm Study of Brain Metastasis in Patients With HER2-positive Breast Cancer

Who this might be right for
TTP
Tianjin Medical University Cancer Institute and Hospital 43
Early research (Phase 1)Ended earlyNCT02964507
What this trial is testing

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

Who this might be right for
Neoplasms
GlaxoSmithKline 124
Next Page